Overcoming asset transfer challenges during a merger and acquisition (M&A)

In this video, Parexel’s Paul Bridges speaks with Phil Smith about how pharma and biotech can overcome common operational challenges and key considerations for a more successful asset transfer.

Return to Insights Center

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Blog

Three Ways Early-Stage Companies Can Attract Investors

Feb 3, 2022